#USA #Kirkland #Hepatitis Delta #EIT Pharma #Lonafarnib

Introduction

Dr. Leen Kawas, the CEO of EIT Pharma, made significant waves at the EASL Congress 2026 held in Barcelona from May 27 to May 30, presenting impactful analyses concerning the company’s lonafarnib development program aimed at tackling Chronic Hepatitis Delta (CHD). This event gathered notable experts and industry leaders, creating an ideal platform for Kawas to share pivotal insights from recent clinical advancements.

EIT Pharma and Lonafarnib

Founded in Kirkland, Washington, EIT Pharma focuses on creating innovative therapies for serious viral diseases. Under the leadership of Dr. Kawas, who assumed the role in 2025, the company has made impressive strides in drug development. Notably, lonafarnib, an oral farnesyltransferase inhibitor, is positioned as a key player, emerging as the only late-stage investigational therapy that can be administered orally for the treatment of Chronic Hepatitis Delta. This is particularly significant, considering the limited treatment options available for this serious liver disease.

Key Findings from EASL Congress 2026

During the congress, EIT Pharma shared analyses from the D-LIVR study, which is notable for being the largest clinical trial ever undertaken for chronic hepatitis D, enrolling over 400 participants across 21 nations. The spotlight was on two compelling presentations:

• - Oral Presentation: A phase 3 D-LIVR study revealed that the combination of lonafarnib/ritonavir with peg-interferon alfa resulted in significant histological improvements and inflammation resolution in patients with chronic hepatitis D. This was presented by Dr. Saeed Hamid during the `Viral Hepatitis B/D – New Therapies` session on May 29.
• - Poster Presentation: Another analysis detailed that the combination of lonafarnib/ritonavir, with or without peginterferon, realized rapid and durable responses in chronic hepatitis D. This was presented in the session titled `Viral Hepatitis B and D New therapies, unapproved therapies or strategies` on May 27.

Dr. Kawas highlighted the critical role of these findings by stating, “People living with chronic hepatitis D face a serious and progressive liver disease with limited treatment options. These new analyses from D-LIVR deepen our understanding of lonafarnib-based regimens for CHD treatment.”

Regulatory Progress and Future Directions

Just over a year after revamping the lonafarnib initiative, EIT Pharma has carved out a regulatory pathway forward that includes collaboration with the U.S. FDA and a detailed review of D-LIVR study data. Lonafarnib has achieved notable FDA designations, including Breakthrough Therapy, Fast Track, and Orphan Drug designations, ensuring a clear focus on its potential commercialization. Dr. Kawas announces that additional data from the D-LIVR program will be disseminated in the upcoming months to the medical community.

Expert Opinions

The excitement surrounding the lonafarnib program is echoed by Jeffrey Glenn, M.D., Ph.D., a significant contributor and scientific co-founder at EIT Pharma, who noted the urgency and opportunity this therapy represents for patients with unmet medical needs. Dr. Glenn states, "The renewed momentum behind lonafarnib is truly exciting. As the only oral option in late-stage development for chronic hepatitis D, this program represents a critical opportunity for patients."

Conclusion

Dr. Kawas's robust presence at EASL Congress 2026 not only underscores her and EIT Pharma’s commitment to advancing healthcare but also sheds light on the company’s relentless pursuit of innovative treatment solutions. With lonafarnib at the forefront, EIT Pharma is committed to addressing the high unmet medical needs faced by patients battling chronic hepatitis D. The proactive role that Dr. Kawas plays in advocating for patient-centered development and enhancing diversity in biotechnology deserves recognition as the field continues to evolve.

As EIT Pharma forges ahead, the anticipation surrounding lonafarnib serves as a beacon of hope for countless individuals affected by Chronic Hepatitis Delta. The collaboration and dedication showcased at the congress indicate a promising future for enhanced therapeutic options in the realm of viral diseases.